| Drug Name | GPCR-targeted Project 003 |
| Description |
The RSPO family of four secreted glycoproteins (RSPO 1-4) acts as potent activators of the Wnt/β-catenin signaling pathway, which has been implicated in the development and growth of multiple tumor types, including ovarian, lung and pancreatic cancers. A humanized monoclonal antibody against RSPO3 is under development and showed potential immunostimulation and anti-tumor activity in preclinical studies. |
| Target | R-spondin 3 (RSPO3) |
| Drug Modality | Monoclonal antibody |
| Indication | Cancers |
| Product Category | Biologic |
| Mechanism of Action | RSPO3 antagonists |
| Status | Preclinical |
| Patent | Granted |
We look forward to hearing from you.
Protheragen's business is growing rapidly after founded in Ronkonkoma, New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.
 |
Protheragen Inc. |
 |
Quick Links |